Plunkett Research Online: Avadel Pharmaceuticals plc

AVADEL PHARMACEUTICALS PLC (AVDL:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Avadel Pharmaceuticals plc is an emerging biopharmaceutical company. The firm’s primary focus is the development and potential U.S. Food and Drug Administration (FDA) approval of FT218, which has completed a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive da.....



Avadel Pharmaceuticals plc
Ticker: AVDL
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 011-1-485-1200
Fax:
Address: 10 Earlsfort Terrace
Dublin 2
Dublin, D02 T380 Ireland

Types Of Business
Industry Ranks

Industry NAICS code:

Drug Delivery Systems
Extended-Release Formulations
Collagen-Based Biomaterials
Long-Acting Insulin
ContactsDescription

Gregory J. DivisCEO
Thomas S. McHughCFO
See More
Avadel Pharmaceuticals plc is an emerging biopharmaceutical company. The firm’s primary focus is the development and potential U.S. Food and Drug Administration (FDA) approval of FT218, which has completed a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive da.....See More See More

Auditor: Deloitte & Touche LLP
Legal Advisor: Hogan & Hartson LLP
$USD, In whole numbers,
except marked * or %
201920182017201620152014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
FT218
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: